Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
0.271
USD
|
-1.09%
|
|
+0.37%
|
-88.52%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
229.4
|
179.8
|
74.5
|
158.8
|
152
|
17.47
|
-
|
-
|
Enterprise Value (EV)
1 |
229.4
|
179.8
|
74.5
|
158.8
|
152
|
17.47
|
17.47
|
17.47
|
P/E ratio
|
-3.95
x
|
-3.36
x
|
-1.17
x
|
-3.4
x
|
-4.07
x
|
-0.43
x
|
-0.54
x
|
-0.47
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
17.7
x
|
64.2
x
|
2,118
x
|
15,197
x
|
-
|
6.54
x
|
18.4
x
|
EV / Revenue
|
-
|
17.7
x
|
64.2
x
|
2,118
x
|
15,197
x
|
-
|
6.54
x
|
18.4
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-4.4
x
|
-4.57
x
|
-1.3
x
|
-3.41
x
|
-
|
-0.43
x
|
-0.41
x
|
-0.3
x
|
FCF Yield
|
-22.7%
|
-21.9%
|
-77.2%
|
-29.3%
|
-
|
-235%
|
-243%
|
-338%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
43,360
|
47,829
|
51,739
|
52,424
|
64,393
|
64,451
|
-
|
-
|
Reference price
2 |
5.290
|
3.760
|
1.440
|
3.030
|
2.360
|
0.2710
|
0.2710
|
0.2710
|
Announcement Date
|
2/28/20
|
3/2/21
|
3/3/22
|
3/29/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
10.16
|
1.16
|
0.075
|
0.01
|
-
|
2.672
|
0.95
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-61.39
|
-51.51
|
-63.45
|
-47.4
|
-39.28
|
-41.35
|
-41.97
|
-47.81
|
Operating Margin
|
-
|
-506.83%
|
-5,469.57%
|
-63,204%
|
-392,750%
|
-
|
-1,570.36%
|
-5,032.58%
|
Earnings before Tax (EBT)
1 |
-57.89
|
-51.03
|
-63.43
|
-46.69
|
-36.9
|
-44.47
|
-52.6
|
-61.62
|
Net income
1 |
-57.89
|
-51.03
|
-63.43
|
-46.69
|
-36.9
|
-40.84
|
-41.81
|
-48.03
|
Net margin
|
-
|
-502.09%
|
-5,467.84%
|
-62,250.67%
|
-368,990%
|
-
|
-1,564.48%
|
-5,055.47%
|
EPS
2 |
-1.340
|
-1.120
|
-1.230
|
-0.8900
|
-0.5800
|
-0.6250
|
-0.4975
|
-0.5725
|
Free Cash Flow
1 |
-52.13
|
-39.31
|
-57.5
|
-46.54
|
-
|
-41
|
-42.5
|
-59
|
FCF margin
|
-
|
-386.8%
|
-4,957.28%
|
-62,055.57%
|
-
|
-
|
-1,590.27%
|
-6,210.53%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/20
|
3/2/21
|
3/3/22
|
3/29/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.018
|
-
|
0.075
|
-
|
-
|
-
|
-
|
-
|
0.01
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-17.43
|
-14.66
|
-13.35
|
-8.768
|
-10.62
|
-10.94
|
-8.93
|
-9.814
|
-9.591
|
-11.12
|
-10.79
|
-11.39
|
-10.16
|
-10.7
|
-12.7
|
Operating Margin
|
-96,811.11%
|
-
|
-17,804%
|
-
|
-
|
-
|
-
|
-
|
-95,910%
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-17.42
|
-14.65
|
-13.27
|
-8.524
|
-10.24
|
-10.36
|
-8.259
|
-9.203
|
-9.079
|
-10.74
|
-11.35
|
-11.88
|
-10.25
|
-10.7
|
-12.7
|
Net income
1 |
-17.42
|
-14.65
|
-13.27
|
-8.524
|
-10.24
|
-10.36
|
-8.259
|
-9.203
|
-9.079
|
-10.74
|
-10.66
|
-10.52
|
-8.756
|
-10.7
|
-12.7
|
Net margin
|
-96,788.89%
|
-
|
-17,689.33%
|
-
|
-
|
-
|
-
|
-
|
-90,790%
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.3300
|
-0.2800
|
-0.2500
|
-0.1600
|
-0.1900
|
-0.1700
|
-0.1300
|
-0.1400
|
-0.1400
|
-0.1700
|
-0.1625
|
-0.1675
|
-0.1325
|
-0.1500
|
-0.2000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/22
|
4/28/22
|
8/3/22
|
11/9/22
|
3/29/23
|
5/3/23
|
8/2/23
|
11/3/23
|
3/27/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-52.1
|
-39.3
|
-57.5
|
-46.5
|
-
|
-41
|
-42.5
|
-59
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.14
|
0.07
|
0.01
|
0.08
|
-
|
1
|
3
|
5
|
Capex / Sales
|
-
|
0.67%
|
1.29%
|
112.25%
|
-
|
-
|
112.25%
|
526.32%
|
Announcement Date
|
2/28/20
|
3/2/21
|
3/3/22
|
3/29/23
|
3/27/24
|
-
|
-
|
-
|
Last Close Price
0.271
USD Average target price
0.75
USD Spread / Average Target +176.75% Consensus |
1st Jan change
|
Capi.
|
---|
| -88.52% | 17.47M | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|